Skip Navigation

Programs

B-Cell NHL & HL

The division of stem cell immunotherapy coordinates care for patients with non-Hodgkin's lymphoma and Hodgkin's lymphoma. Active clinical researched studies are testing and evaluating the safety and efficacy of novel compounds to treat these illnesses. Transplant protocols utilized high dose chemotherapy with stem support for the management of patients with very high risk lymphoma or those patients whose lymphoma has reoccurred after first line treatment. Epidemiological studies are defining the instance of lymphoma in Georgia, and disparities in the management and response to treatment based upon the ethnicity of patients.
Read more...

Clinical Bone Marrow Transplant

The mission of the Emory Bone Marrow and Stem Cell Transplant Program is to provide curative therapy for patients hematologic and other malignancies, as well as other selected nonmalignant blood disorders. We utilize a multidisciplinary team approach to treatment planning and patient care, and we are committed to quality patient care and to the conduct of innovative pre-clinical and clinical research.
Read more...

Emory Personalized Immunotherapy Center

The Emory Personalized Immunotherapy Center is an enabling core enabling facility and program to support early phase clinical trials of cell-based therapies where processing of human cell and tissue is required as part of a FDA-sponsored biopharmaceutical study. The facility is a state of the art sterile manufacturing facility which is operated by a highly qualified team of Clinicians, scientists and technical staff.
Read more...

Myeloma Preclinical Model & Clinical Trials

Emory has one of the largest myeloma programs in the country; enrolling over 100 subjects a year onto investigational drug trials, evaluating new drugs and new combinations of drugs for myeloma. Preclinical models are utilized to define optimal dose and schedule of novel compounds including combinations and sequences of the newer targeted agents. Genomic analyses of primary tumor samples are defining the genetic heterogeneity of myeloma and using gene expression profiling to optimize treatment. Randomized clinical trials are defining optimal approaches for stem cell mobilization and the role of stem cell transplantation in the management of multiple myeloma.
Read more...

Outcomes Research

An active program of outcomes research is available to correlate clinical outcomes with baseline characteristics of patients with lymphoid hematological malignancies as well as stratification on ethnicity and treatment regimens. Networking with statewide cancer lymphoma registries and national lymphoma care registry allow generation of novel insights regarding subsets of patients who may have better or worse outcomes based upon biological characteristics of their tumor or ethnic, racial or social characteristics of the patient population. A statewide tumor sample repository is utilized for interrogation of clinical samples with a goal towards better definition of tumor subtypes and optimal identification of treatment regimen based upon histology, immunophenotype and gene expression arrays.
Read more...

Preclinical BMT Models

The goal of the Program for Preclinical Bone Marrow Transplant Models is to develop new transplant methods that might improve outcomes for patients undergoing bone marrow transplantation. Studies are conducted in cell culture and in animal models in order to develop scientific data to support the rationale for conduct of new clinical trials to evaluate these novel methods.
Read more...

T-Cell NHL Clinical Trials

The Emory stem cell and immunotherapy division is actively investigating optimal management of patients with T-cell NHL, a disease that typically has had poor outcomes to standard chemotherapy. New drugs are tested in clinical trials as well as new drug combinations and management of patients with cutaneous T-cell lymphoma T1+, T-cell NHL and T-cell NHL NOS. Clinical samples from patients with these rare disease entities are available for preclinical testing including cytogenetic analyses and for gene expression arrays.
Read more...